Gaballa Andrew, Hajj Ali Adel, El Dahdah Joseph, Popovic Zoran, Wang Tom K, Reed Grant, Rodriguez Leonardo, Griffin Brian, Gillinov A Marc, Kapadia Samir R, Svensson Lars G, Desai Milind Y
Heart Vascular Thoracic Institute (HVTI), Cleveland Clinic, Cleveland, OH, USA.
Department of Internal Medicine, Indiana University, Indianapolis, IN, USA.
Cardiovasc Diagn Ther. 2025 Feb 28;15(1):265-272. doi: 10.21037/cdt-24-324. Epub 2025 Feb 25.
Calcium supplement intake, with or without vitamin D supplementation, has risen amongst the older population, who are more likely to have deficiencies. Our aim was to investigate how the supplementation of calcium and vitamin D is associated with survival in patients with moderate concomitant aortic and mitral valve disease. A total of 3,257 patients (mean age of 71.73 years; 55.2% male; 83.1% White) were diagnosed with moderate concomitant aortic and mitral valve disease at Cleveland Clinic between January 2010 and December 2020 and were included in this study. The patients were divided into two groups based on their supplement intake. Further subgroup analysis was performed, focusing on the aortic valve, leading to the stratification of patients into two subgroups-group 1: aortic stenosis (AS) combined with either mitral stenosis or regurgitation, and group 2: aortic regurgitation (AR) combined with either mitral stenosis or regurgitation. The study's primary outcome was the combined event of all-cause mortality and heart failure hospitalization. Of the 3,257 patients who were included, 70% of them (2,273 patients) did not receive supplements, and 30% (984 patients) had received calcium and vitamin D supplementation. The supplement intake was associated with a greater risk of all-cause mortality [hazard ratio (HR), 1.114; 95% confidence interval (CI): 1.003-1.237, P=0.043], but no significant association with heart failure hospitalization was observed (HR, 1.003; 95% CI: 0.884-1.139, P=0.96). The subgroup analysis based on the aortic valve showed that among the 1,045 patients in group 1, 67% did not receive supplements, and 33% received supplementation. Calcium and vitamin D supplementation was significantly associated with a greater risk of all-cause mortality in patients with AS (HR, 1.203; 95% CI: 1.017-1.425, P=0.03). Contrarywise, in group 2 of patients with AR consisting of 2,212 patients, 71% did not receive any supplementation, and 29% received supplementation, with no significant association observed (HR, 1.044; 95% CI: 0.913-1.193, P=0.53). To conclude, in patients diagnosed with moderate concomitant aortic and mitral valve disease, the use of calcium and vitamin D supplements was associated with a greater mortality rate, particularly in AS patients.
在老年人中,无论是否补充维生素D,钙补充剂的摄入量都有所增加,而老年人更有可能存在缺乏症。我们的目的是研究钙和维生素D补充剂与中度主动脉瓣和二尖瓣疾病患者生存率之间的关系。2010年1月至2020年12月期间,克利夫兰诊所共诊断出3257例中度主动脉瓣和二尖瓣疾病患者(平均年龄71.73岁;男性占55.2%;白人占83.1%)并纳入本研究。根据补充剂摄入量将患者分为两组。进一步进行亚组分析,重点关注主动脉瓣,将患者分为两个亚组——第1组:主动脉瓣狭窄(AS)合并二尖瓣狭窄或反流,第2组:主动脉瓣反流(AR)合并二尖瓣狭窄或反流。该研究的主要结局是全因死亡率和心力衰竭住院的联合事件。在纳入的3257例患者中,70%(2273例患者)未接受补充剂,30%(984例患者)接受了钙和维生素D补充剂。补充剂摄入与全因死亡风险增加相关[风险比(HR),1.114;95%置信区间(CI):1.003 - 1.237,P = 0.043],但未观察到与心力衰竭住院有显著关联(HR,1.003;95%CI:0.884 - 1.139,P = 0.96)。基于主动脉瓣的亚组分析显示,在第1组的1045例患者中,67%未接受补充剂,33%接受了补充剂。钙和维生素D补充剂与AS患者全因死亡风险增加显著相关(HR,1.203;95%CI:1.017 - 1.425,P = 0.03)。相反,在由2212例患者组成的AR第2组中,71%未接受任何补充剂,29%接受了补充剂,未观察到显著关联(HR,1.044;95%CI:0.913 - 1.193,P = 0.53)。总之,在诊断为中度主动脉瓣和二尖瓣疾病的患者中,使用钙和维生素D补充剂与更高的死亡率相关,尤其是在AS患者中。